Suppr超能文献

血管紧张素转换酶抑制可预防Thy-1.1转基因小鼠中塌陷型局灶节段性肾小球硬化的发展。

Angiotensin converting enzyme inhibition prevents development of collapsing focal segmental glomerulosclerosis in Thy-1.1 transgenic mice.

作者信息

Smeets Bart, Steenbergen Mark L M, Dijkman Henry B P M, Verrijp Kiek N, te Loeke Nathalie A J M, Aten Jan, Steenbergen Eric J, Wetzels Jack F M

机构信息

Department of Pathology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

出版信息

Nephrol Dial Transplant. 2006 Nov;21(11):3087-97. doi: 10.1093/ndt/gfl495. Epub 2006 Sep 12.

Abstract

BACKGROUND

Thy-1.1 transgenic mice develop hypercellular focal and segmental glomerulosclerosis (FSGS) lesions that mimic human collapsing FSGS, in 7 days after injection with anti-Thy-1.1 antibodies. These lesions consist of proliferating parietal epithelial cells (PECs). We questioned whether the angiotensin converting enzyme inhibitor (ACE), captopril, could prevent the development of FSGS and if protection is related to the timing of drug administration.

METHODS

First, we compared the effect of captopril treatment with angiotensin II-(ANGII) independent antihypertensive therapy (triple therapy). Second, we tested the effects of captopril administered over four different time intervals: days -7 to 0 (Ca-7>0), days -7 to 7 (Ca-7>7), days 0-7 (Ca0>7) and days 3-7 (Ca3>7) (day 0 being the day of injection of the antibody).

RESULTS

In anti-Thy-1.1 injected control (C) mice we observed dedifferentiation and activation of podocytes, reflected by loss of ASD33 and increased expression of desmin, followed by a marked accumulation of PECs forming hypercellular lesions. PECs showed an increased expression of connective tissue growth factor (CTGF). Triple therapy or captorpil pre-treatment (Ca-7>0) had no significant effect on albuminuria or FSGS. In contrast, Ca0>7 and Ca3>7 treatment significantly lowered albuminuria and attenuated development of FSGS. The latter two treatments attenuated loss of ASD33 expression by podocytes but could not prevent increased desmin expression. In addition, these treatments reduced CTGF expression by PECs and prevented PEC proliferation.

CONCLUSIONS

ACE inhibition, but not triple therapy, prevents the development of FSGS, suggesting an important role for ANGII. ACE inhibition has a protective effect even when started 3 days after the initial podocyte insult, which is probably related to the ability of ACE-inhibition to block PEC activation and proliferation.

摘要

背景

Thy-1.1转基因小鼠在注射抗Thy-1.1抗体7天后会出现细胞增多性局灶节段性肾小球硬化(FSGS)病变,类似于人类塌陷性FSGS。这些病变由增殖的壁层上皮细胞(PEC)组成。我们质疑血管紧张素转换酶抑制剂(ACE)卡托普利是否能预防FSGS的发展,以及保护作用是否与药物给药时间有关。

方法

首先,我们比较了卡托普利治疗与不依赖血管紧张素II(ANGII)的抗高血压治疗(三联疗法)的效果。其次,我们测试了在四个不同时间间隔给予卡托普利的效果:第-7天至0天(Ca-7>0)、第-7天至7天(Ca-7>7)、第0天至7天(Ca0>7)和第3天至7天(Ca3>7)(第0天为注射抗体的日子)。

结果

在注射抗Thy-1.1的对照(C)小鼠中,我们观察到足细胞去分化和激活,表现为ASD33丢失和结蛋白表达增加,随后PEC明显积聚形成细胞增多性病变。PEC显示结缔组织生长因子(CTGF)表达增加。三联疗法或卡托普利预处理(Ca-7>0)对蛋白尿或FSGS无显著影响。相比之下,Ca0>7和Ca3>7治疗显著降低了蛋白尿并减轻了FSGS的发展。后两种治疗减轻了足细胞ASD33表达的丢失,但不能阻止结蛋白表达增加。此外,这些治疗降低了PEC的CTGF表达并阻止了PEC增殖。

结论

ACE抑制而非三联疗法可预防FSGS的发展,提示ANGII起重要作用。即使在初始足细胞损伤3天后开始ACE抑制也具有保护作用,这可能与ACE抑制阻断PEC激活和增殖的能力有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验